Shots:  

• The approval is based on the P-lll BELIEVE study assessing Reblozyl (luspatercept) + BSC vs PBO + BSC in adult patients with anemia associated with beta-thalassemia requiring regular RBC transfusions
• Result: ≥33% reduction in RBC transfusion with a reduction of ≥2units from 13-24wks. (21.4% vs. 4.5%)- results were published in NEJM
• Reblozyl regulate late-stage RBC maturation to potentially reduce the number of regular RBC transfusions and is the first and only erythroid maturation agent approved in Canada

­ Ref: BMS | Image: BMS